RANITIN 150, 300 mg

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.

Abbreviated Prescribing information for RANITIN 150, 300 mg (Ranitidine Hydrochloride Tablets I.P.**)**

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

Mechanism of action: Pharmacotherapeutic group: H2-receptor antagonists

ATC code: A02BA02

Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion.

DOSAGE AND ADMINISTRATION: The usual dosage is 150 mg twice daily, taken in the morning and evening. Patients with duodenal ulceration, gastric ulceration or oesophageal reflux disease may be treated with a single bedtime dose of 300 mg or as directed by physician.

CONTRAINDICATION: Hypersensitivity to the active substance or to any of the excipients.

WARNINGS & PRECAUTIONS: Malignancy, renal Disease, bradycardia, acute porphyric attacks, in elderly patients, persons with chronic lung disease, diabetes or the immunocompromised increased risk of developing community acquired pneumonia. Post-marketing data indicate reversible mental confusion, depression, and hallucinations, reported most frequently in severely ill and elderly patients.

DRUG INTERACTION: 1) Inhibition of cytochrome P450-linked mixed function oxygenase system: does not potentiate the actions of drugs, which are inactivated by this enzyme system such as diazepam, lidocaine, phenytoin, propranolol and theophylline. Also, altered prothrombin time with coumarin anticoagulants (e.g. warfarin). 2) Competition for renal tubular secretion: may reduce the excretion of procainamide and N-acetylprocainamide. 3) Alteration of gastric pH: increase in absorption (e.g. triazolam, midazolam, glipizide) or a decrease in absorption (e.g. ketoconazole, atazanavir, delaviridine, gefitnib, also decreases erlotinib exposure.

ADVERSE REACTIONS: Leucopenia, thrombocytopenia, agranulocytosis or pancytopenia, with marrow hypoplasia or marrow aplasia, Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension and chest pain), Anaphylactic shock, Dyspnoea, Reversible mental confusion, depression and hallucinations, Headache (sometimes severe), dizziness and reversible involuntary movement disorder, blurred vision, bradycardia, A-V block, asystole, cardiac arrest and tachycardia, Vasculitis, abdominal pain, constipation, nausea, acute pancreatitis, diarrhoea, Hepatitis, Skin Rash, Erythema multiforme, alopecia, arthralgia and myalgia, Acute interstitial nephritis, impotence, breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea.

Marketed BY:

Torrent Pharmaceuticals Ltd.
32 No, Middle Camp,
NH-10, East District, Gangtok, Sikkim-737 135

IN/RANITIN 150,300 mg/FEB-2022/04/ABPI

(Additional information is available on request)